Cervical cancer
Conditions
Interventions
Experimental group:Iparomlimab and Tuvonalimab Injection+Albumin-bound paclitaxel + carboplatin
Sponsors
Fudan University Shanghai Cancer Center
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Female patients aged between 18 and 75 years old. 2. Pathologically diagnosed with cervical squamous cell carcinoma, adenocarcinoma or adenocarcinoma-squamous cell carcinoma. 3. Clinical stage of IB3, IIA2 or = 4cm IIIC1r (FIGO 2018 standard). 4. Expected survival period of at least 6 months. 5. ECOG performance status score of 0-1. 6. Possessing adequate organ function. 7. Agreeing and signing the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Has received systemic treatment for cervical cancer (including radiotherapy, chemotherapy, immunotherapy, etc.). 2. Has active or uncontrolled infections, including HIV, HBV and HCV infections. 3. Has a history of immunodeficiency disease or has received immunosuppressive therapy (such as organ transplantation, chronic hormone therapy, etc.). 4. Has other serious systemic diseases, such as uncontrolled hypertension, diabetes, heart disease, etc. 5. Has central nervous system metastasis or meningeal metastasis. 6. Has a history of other malignant tumors (unless already cured and without recurrence signs). 7. Pregnant or lactating women, or women planning to get pregnant during the study period. 8. Has a known allergic reaction to epalorlimovaluriabulin or albumin paclitaxel, or platinum-based drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete remission rate(pCR);Objective remission rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Progression free survival;Surgical clearance rate;Surgical complication;The proportion of postoperative adjuvant therapy; | — |
Countries
China
Contacts
Public ContactXingzhu Ju
Fudan University Shanghai Cancer Center
Outcome results
None listed